BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 291947)

  • 21. Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. Polypeptide sequence determination and assignment of the oligosaccharide attachment site in C5a.
    Fernandez HN; Hugli TE
    J Biol Chem; 1978 Oct; 253(19):6955-64. PubMed ID: 690134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The active site of C3a anaphylatoxin.
    Caporale LH; Tippett PS; Erickson BW; Hugli TE
    J Biol Chem; 1980 Nov; 255(22):10758-63. PubMed ID: 6968751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Purification and partial amino acid sequence of classical anaphylatoxin from pig serum: identification with Des-Arg-C5a.
    Zimmermann B; Damerau B; Vogt W
    Hoppe Seylers Z Physiol Chem; 1980; 361(6):915-24. PubMed ID: 7399411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radioimmunoassay for anaphylatoxins: a sensitive method for determining complement activation products in biological fluids.
    Wagner JL; Hugli TE
    Anal Biochem; 1984 Jan; 136(1):75-88. PubMed ID: 6711816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potentiation of the anaphylatoxins in vivo using an inhibitor of serum carboxypeptidase N (SCPN). I. Lethality and pathologic effects on pulmonary tissue.
    Huey R; Bloor CM; Kawahara MS; Hugli TE
    Am J Pathol; 1983 Jul; 112(1):48-60. PubMed ID: 6859228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A recombinant hybrid anaphylatoxin with dual C3a/C5a activity.
    Bautsch W; Kretzschmar T; Stühmer T; Kola A; Emde M; Köhl J; Klos A; Bitter-Suermann D
    Biochem J; 1992 Nov; 288 ( Pt 1)(Pt 1):261-6. PubMed ID: 1445269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anaphylatoxin levels in human aqueous humor.
    Mondino BJ; Sumner H
    Invest Ophthalmol Vis Sci; 1986 Aug; 27(8):1288-92. PubMed ID: 3488296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. C4a: An Anaphylatoxin in Name Only.
    Barnum SR
    J Innate Immun; 2015; 7(4):333-9. PubMed ID: 25659340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mast cells are not required for anaphylatoxin-induced ileal smooth muscle contraction.
    Stimler-Gerard NP; Galli SJ
    J Immunol; 1987 Mar; 138(6):1908-13. PubMed ID: 2434565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complement anaphylatoxins in idiopathic mixed cryoglobulinemia.
    Miadonna A; Leggieri E; Tedeschi A; Cottini M; Invernizzi F; Froldi M; Zanussi C
    Int Arch Allergy Appl Immunol; 1985; 76(2):120-5. PubMed ID: 3967939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Demonstration of anaphylatoxins C3a, C4a and C5a in the scales of psoriasis and inflammatory pustular dermatoses.
    Takematsu H; Ohkohchi K; Tagami H
    Br J Dermatol; 1986 Jan; 114(1):1-6. PubMed ID: 3484631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human C5a des Arg increases vascular permeability.
    José PJ; Forrest MJ; Williams TJ
    J Immunol; 1981 Dec; 127(6):2376-80. PubMed ID: 6170701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma anaphylatoxin concentrations in inflammatory skin diseases.
    Terui T; Takematsu H; Kato T; Ohkohchi K; Tagami H
    Tohoku J Exp Med; 1987 Feb; 151(2):245-52. PubMed ID: 3495048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary structure of bovine complement activation fragment C4a, the third anaphylatoxin. Purification and complete amino acid sequence.
    Smith MA; Gerrie LM; Dunbar B; Fothergill JE
    Biochem J; 1982 Nov; 207(2):253-60. PubMed ID: 6760852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of histamine in the spasmogenic effect of the complement peptides C3a and C5a-desArg (classical anaphylatoxin).
    Sorgenfrei J; Damerau B; Vogt W
    Agents Actions; 1982 Apr; 12(1-2):118-21. PubMed ID: 6177210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anaphylatoxin levels in human vitreous humor.
    Mondino BJ; Sidikaro Y; Sumner H
    Invest Ophthalmol Vis Sci; 1988 Jul; 29(7):1195-8. PubMed ID: 3262096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anaphylatoxin generation in multisystem organ failure.
    Heideman M; Hugli TE
    J Trauma; 1984 Dec; 24(12):1038-43. PubMed ID: 6334754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of human serum complement with allergens. I. Generation of C3a, C4a, and C5a and induction of human neutrophil aggregation.
    Nagata S; Glovsky MM
    J Allergy Clin Immunol; 1987 Jul; 80(1):24-32. PubMed ID: 3496373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of human anaphylatoxins on guinea pig atria.
    Huey R; Bloor CM; Hugli TE
    Immunopharmacology; 1984 Dec; 8(3-4):147-54. PubMed ID: 6335143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complement mediated inhibition of immune precipitation and solubilization generate different concentrations of complement anaphylatoxins (C4a, C3a, C5a).
    Schifferli JA; Steiger G; Paccaud JP
    Clin Exp Immunol; 1986 May; 64(2):407-14. PubMed ID: 3488858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.